2 citations
,
May 2025 in “Archives of Dermatological Research” JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
2 citations
,
June 2024 in “Journal of the American Academy of Dermatology” Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
2 citations
,
May 2022 in “Cosmetics” Further research is needed to understand how the microbiome affects hair loss in Alopecia Areata.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
1 citations
,
February 2025 in “Medicina” No significant genetic link to alopecia areata was found in the Jordanian group.
1 citations
,
December 2023 in “International journal of molecular sciences” miR-199a-3p controls hair growth and is linked to alopecia areata.
1 citations
,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
1 citations
,
October 2022 in “International Journal of Molecular Sciences” Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.